Long anticipated – now available: the neurology portfolio for the UNIQO 160, our all-in-one automated IFA system, has been expanded by nine more indirect immunofluorescence assays (IFA). While the previous portfolio primarily contained classic Euroimmun BIOCHIP Mosaics with different tissue sections as substrates, these new additions are highly relevant monospecific IFA with a particular focus on optimising the diagnostics for autoimmune encephalitis using cell-based assays (CBA).
More than 40% of the global population is affected by confirmed neurological conditions, which have now surpassed cardiovascular disorders as the most common group of diseases worldwide. 1 Therefore, comprehensive serological support for neurological diagnostics is increasingly important in order to produce an early disease-specific diagnosis and to initiate targeted therapy.
The expanded UNIQO portfolio now enables the automated analysis of parameters such as antibodies against specific neuronal receptors, including glutamate receptors (NMDA and AMPA1/2) and GABAB receptor (GABARB1/B2), and against important surface proteins such as contactin-associated protein 2 (CASPR2), dipeptidyl aminopeptidase-like protein 6 (DPPX) and leucine-rich glioma-inactivated protein 1 (LGI1). The whole process is carried out on a single instrument, encompassing the incubation and mounting of slides, as well as the microscopy and software-aided reporting.
We combine two of our greatest strengths here: decades of experience and visionary concepts in indirect immunofluorescence diagnostics, and proven expertise and passion for neurology.
Discover our unique portfolio for the UNIQO 160 and set new standards in neurological diagnostics together with us.
Do you want to learn more? Find more information on the UNIQO 160 and the corresponding test systems here.
1 Global status report on neurology. Geneva: World Health Organization; 2025.
